A prescription contract, also called a controlled substance agreement or pain management agreement, is a written document signed by both the patient and the prescriber at the initiation of opioid therapy that establishes the mutual expectations and obligations governing the prescribing relationship.
The agreement is not a legal contract in the commercial sense; it does not create enforceable legal obligations between the parties in the way a commercial contract does. It is a clinical tool that documents the patient’s informed consent to opioid therapy, establishes the conditions under which therapy will be continued or discontinued, and creates a record of the patient’s awareness of the risks associated with opioid medications and the behavioral expectations the prescriber has established.
What the Agreement Typically Contains
A well-drafted controlled substance agreement identifies the patient and the prescribing practitioner, describes the medications to be prescribed and the therapeutic goals of the treatment, and establishes the patient’s obligations during the course of therapy. Those obligations typically include: obtaining all controlled substance prescriptions from a single prescriber or practice; not obtaining controlled substances from other providers without notifying the prescribing practitioner; submitting to urine drug screening at the practitioner’s request and without advance notice; not sharing, selling, or otherwise diverting prescribed medications; safeguarding prescription medications from theft or loss; and reporting any lost or stolen medications promptly.
The agreement also typically identifies the consequences of non-compliance: the potential discontinuation of controlled substance prescribing, referral to an addiction medicine specialist if diversion or misuse is identified, and notification of the relevant authorities if criminal conduct is identified. These provisions document the practitioner’s awareness of diversion risk and the clinical framework within which prescribing will be managed.
The Clinical and Legal Significance
From a clinical perspective, the controlled substance agreement serves as a tool for patient education and risk management. Patients who understand the expectations and consequences associated with opioid therapy are more likely to comply with monitoring requirements and less likely to engage in conduct that puts the prescribing relationship at risk. The informed consent function of the agreement reflects the standard of care in chronic opioid therapy management that most clinical guidelines describe.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196From a legal perspective, the controlled substance agreement creates a record that the patient was informed of the risks of opioid therapy, that they agreed to comply with monitoring requirements, and that the prescriber established and communicated behavioral expectations consistent with the clinical management of chronic pain. In the context of a DEA investigation, the agreement demonstrates that the prescribing occurred within a framework of clinical oversight rather than as a commercial transaction.
Enforcement and Documentation
The controlled substance agreement is only as valuable as the practice’s consistent implementation of its terms. An agreement that was signed at the initiation of therapy and never referenced again, that was not accompanied by urine drug screening, pill counts, or other monitoring, and whose violation terms were never enforced, is an agreement that suggests a compliance facade rather than genuine clinical oversight.
The encounter records should reflect that monitoring activities were conducted, that agreement compliance was assessed, and that the clinical decision to continue prescribing was made with awareness of the patient’s compliance status. The patient whose urine drug screen showed no prescribed medication, whose compliance with the agreement’s terms was documented as deficient, and whose prescribing was nonetheless continued without documented clinical justification for the continuation has generated a record that undermines the agreement’s protective value.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
A controlled substance agreement that has not been enforced is a document that helps the government more than it helps the defense. It demonstrates that the practitioner knew what legitimate prescribing oversight required, established those requirements in writing, and then did not follow them. The agreement that is consistently implemented, monitored, and enforced through clinical decisions that reflect its terms is the agreement that supports the defense. The agreement that gathers dust in the patient file supports the prosecution.
State and Clinical Guideline Requirements
Many states have enacted requirements for written controlled substance agreements in chronic opioid therapy, and some states specify the minimum content those agreements must contain. The practitioner whose agreements meet or exceed the applicable state requirements and clinical guideline recommendations has satisfied the most straightforward compliance obligation in the controlled substance prescribing space. The practitioner who did not use agreements at all, in a practice where clinical guidelines and state regulations expected them, has identified a compliance gap that an investigation will note as evidence of prescribing without the clinical oversight framework that legitimate pain management requires.
